Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Techniques & Tools

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / Articles / Mar / Forecasting Medicine Use and Controlling Supply Chains
Business & Regulation Digital Technologies Standards & Regulation Supply Chain Regulation & Standards Business & Trends Supply Chain

Forecasting Medicine Use and Controlling Supply Chains

The role of digital technologies in optimizing traceability in pharmaceutical supply chains.

By Tim Tinnel 03/19/2025 3 min read

Share

Accurately forecasting medication use has long been a pain point within medical systems, as has finding the balance between over- and under-ordering medications (to the detriment of patients). In recent years, this tightrope has been further complicated by ongoing drug shortages and further exacerbated by supply chain disruptions caused by natural disasters. According to the American Society of Health-System Pharmacists (ASHP), a record-high 323 active drug shortages were reported in the first quarter of 2024.  

Drug shortages are complex, multifaceted problems requiring solutions at various points across the drug pipeline. While some elements can only be addressed at the manufacturer level or via regulators, others are controlled by hospitals, such as how medications are ordered and managed.  

A digital transformation is now underway to enhance the visibility, tracking, and management of every vial. This evolution has far-reaching benefits, from helping stakeholders to navigate shortages, to providing visibility in the event of a drug recall, to protecting patient safety. Interoperability, or the ability of systems and platforms to work together through the sharing of data and insights, is a major limiting factor for collaboration across medication supply chains. It requires disparate technologies and platforms to speak the same language. With a shared language, the totality of information can be pooled and analyzed in a myriad of different ways to streamline areas such as inventory management.  

Digital, interoperable platforms are also capable of helping to address regulatory challenges, such as Drug Supply Chain Security Act (DSCSA) requirements for visibility into the lifecycle of medications from manufacturer to hospital. In the future, it’s entirely feasible to imagine these systems evolving to make the most of machine learning and AI, exponentially increasing their value.  

Better tracking technology
 

It all starts with tracking technology. Standards must be in place to ensure that the data being fed into a tracking system is high-quality, timely, and reliable. With traditional barcode-based medication tracking, data quality can be hard to qualify and is prone to human error. To address this, leading organizations throughout the pharmaceutical supply chain – from drug manufacturers and distributors through to health systems – are transitioning to radio frequency identification (RFID) technology. RFID allows medications to be tagged and tracked with a high level of accuracy from the manufacturer to the point of care, generating a wealth of reliable unit-level data. Applying standards to the use of this technology ensures this data is high quality and universal. In the case of RFID technology, GS1 standards are quickly becoming the industry gold standard.  

In the near term, this data can help monitor the location and status of medications with reduced manual intervention and overheads. During a shortage, this level of insight can be invaluable, reducing stockouts and helping ensure continuity of operations. Longer-term, this comprehensive medication data can be analyzed to give a clear and accurate view of usage trends. Empowered with these insights, stakeholders can make informed inventory decisions such as rationing supply across a system during an active shortage or limiting the over-purchase of medications to alleviate pressure on the supply chain. 

An insightful future
 

In the same way that high-quality data and interoperable systems can enable supply chain visibility and medication management across systems, they can also improve day-to-day workflows. By making it more seamless to gather inventory data, time to focus on core responsibilities and enable a more seamless flow of information is gained.  

In my view, the future of medication management lies in harnessing data to empower manufacturers. Through this data, companies will be empowered to optimize supply chains, enhance patient safety, and meet regulatory requirements effectively. The insights enabled through new technologies, including AI, are near-limitless. Paired with accurate data through RFID technology and broader interoperability, they will unlock unprecedented opportunities for efficiency and innovation, ultimately transforming how drugs are transported and managed across the life sciences ecosystem. By adopting these solutions, the pharmaceutical industry not only addresses its current challenges but also paves the way for a more resilient and patient-focused future. 

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Tim Tinnel

Executive Vice President/Chief Operating Officer of Intelliguard. With more than 25 years of consultative experience in supply chain, operations, and technology leadership roles and a proven track record of driving transformation, operational excellence, customer satisfaction, and business growth, Tim is a vendor relations and process improvement expert. At Intelliguard, he works to leverage analytics, AI, and automation to optimize performance and efficiency, empowering clients to achieve better outcomes and quality of care.

More Articles by Tim Tinnel

False

Advertisement

Recommended

False

Related Content

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Partnership Cuts Cost of CAR T Manufacturing
Advanced Medicine Technology and Equipment Digital Technologies
Partnership Cuts Cost of CAR T Manufacturing

March 13, 2025

4 min read

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that? Trenchant and Autolomous explore the possibilities.

Forecasting Medicine Use and Controlling Supply Chains
Digital Technologies Standards & Regulation Supply Chain
Forecasting Medicine Use and Controlling Supply Chains

March 19, 2025

3 min read

The role of digital technologies in optimizing traceability in pharmaceutical supply chains.

AI, Big Data, and Digital Disruption
Digital Technologies Clinical Trials
AI, Big Data, and Digital Disruption

March 31, 2025

7 min read

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.